相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival
Bernhard Mlecnik et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Implications of the tumor immune microenvironment for staging and therapeutics
Janis M. Taube et al.
MODERN PATHOLOGY (2018)
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan et al.
SCIENCE (2018)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line
Diogo Gomes-Silva et al.
BIOTECHNOLOGY JOURNAL (2018)
Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival
Bernhard Mlecnik et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Small Molecules Drive Big Improvements in Immuno-Oncology Therapies
Bayard R. Huck et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2018)
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
Rizwan Romee et al.
BLOOD (2018)
Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy
Xiaojing Xu et al.
CANCER SCIENCE (2018)
Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer
Allen W. Zhang et al.
CELL (2018)
NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
Jan P. Boettcher et al.
CELL (2018)
TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy
Lan Huang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cancer immunotherapy beyond immune checkpoint inhibitors
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
Franck Pages et al.
LANCET (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
Jonathan T. Sockolosky et al.
SCIENCE (2018)
'Liquid biopsy' for cancer promises early detection Combining DNA and protein markers brings researchers closer to a universal cancer screening test
Jocelyn Kaiser
SCIENCE (2018)
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Vyara Matson et al.
SCIENCE (2018)
Eradication of spontaneous malignancy by local immunotherapy
Idit Sagiv-Barfi et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment
David L. Elion et al.
Oncotarget (2018)
Exploring the single-cell RNA-seq analysis landscape with the scRNA-tools database
Luke Zappia et al.
PLOS COMPUTATIONAL BIOLOGY (2018)
Further Advances in Cancer immunotherapy: Going Beyond Checkpoint Blockade
Robert W. Wilkinson et al.
FRONTIERS IN IMMUNOLOGY (2018)
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
Aurelie Durgeau et al.
FRONTIERS IN IMMUNOLOGY (2018)
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
Elena Garcia-Martinez et al.
ONCOIMMUNOLOGY (2018)
Targeting adenosine for cancer immunotherapy
Robert D. Leone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient
Andreas Wieland et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Michal A. Stanczak et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
High response rate to PD-1 blockade in desmoplastic melanomas
Zeynep Eroglu et al.
NATURE (2018)
In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma
Matthew J. Frank et al.
CANCER DISCOVERY (2018)
Evolution of Metastases in Space and Time under Immune Selection
Mihaela Angelova et al.
CELL (2018)
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
Razvan Cristescu et al.
SCIENCE (2018)
Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma
Clemence Granier et al.
CANCER RESEARCH (2017)
First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas
Sylvie Bonvalot et al.
CLINICAL CANCER RESEARCH (2017)
Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN
Laura Q. M. Chow et al.
CLINICAL CANCER RESEARCH (2017)
Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists
Gregory L. Beatty et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
Impact of inhibitor of apoptosis proteins on immune modulation and inflammation
Sachin Sharma et al.
IMMUNOLOGY AND CELL BIOLOGY (2017)
Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
Gulidanna Shayan et al.
ONCOIMMUNOLOGY (2017)
Modulation of cancer-specific immune responses by amino acid degrading enzymes
Elina Timosenko et al.
IMMUNOTHERAPY (2017)
TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
Wenwen Du et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Epithelial-mesenchymal transition in cancer
Aristidis Moustakas et al.
MOLECULAR ONCOLOGY (2017)
EMT and MET: necessary or permissive for metastasis?
Mohit Kumar Jolly et al.
MOLECULAR ONCOLOGY (2017)
New insights into the role of EMT in tumor immune escape
Stephane Terry et al.
MOLECULAR ONCOLOGY (2017)
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin et al.
NATURE (2017)
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Justin Eyquem et al.
NATURE (2017)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang et al.
NATURE (2017)
Mitotic progression following DNA damage enables pattern recognition within micronuclei
Shane M. Harding et al.
NATURE (2017)
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Lin Tian et al.
NATURE (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Jianjun Gao et al.
NATURE MEDICINE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tragedy, Perseverance, and Chance - The Story of CAR-T Therapy
Lisa Rosenbaum
NEW ENGLAND JOURNAL OF MEDICINE (2017)
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
Enfu Hui et al.
SCIENCE (2017)
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent
Alice O. Kamphorst et al.
SCIENCE (2017)
Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
Teresa Davoli et al.
SCIENCE (2017)
Post-Translational Peptide Splicing and T Cell Responses
Michele Mishto et al.
TRENDS IN IMMUNOLOGY (2017)
TIGIT: A Key Inhibitor of the Cancer Immunity Cycle
Nicholas A. Manieri et al.
TRENDS IN IMMUNOLOGY (2017)
Type I Interferon in Chronic Virus Infection and Cancer
Laura M. Snell et al.
TRENDS IN IMMUNOLOGY (2017)
Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy
Tianchi Yu et al.
YONSEI MEDICAL JOURNAL (2017)
Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
Martin Lauss et al.
NATURE COMMUNICATIONS (2017)
Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells
Paul E. Clavijo et al.
ONCOTARGET (2017)
Concise Review: Cancer Cells, Cancer Stem Cells, and Mesenchymal Stem Cells: Influence in Cancer Development
Federica Papaccio et al.
STEM CELLS TRANSLATIONAL MEDICINE (2017)
A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice
Jeremy B. Foote et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model
Janne Nestvold et al.
ONCOIMMUNOLOGY (2017)
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Michael A. Cannarile et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy
A. R. Sanchez-Paulete et al.
ANNALS OF ONCOLOGY (2017)
Emergence of High-Avidity Melan-A-Specific Clonotypes as a Reflection of Anti-PD-1 Clinical Efficacy
Sylvain Simon et al.
CANCER RESEARCH (2017)
xCell: digitally portraying the tissue cellular heterogeneity landscape
Dvir Aran et al.
GENOME BIOLOGY (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
Migrating into the Tumor: a Roadmap for T Cells
Lieke L. van der Woude et al.
TRENDS IN CANCER (2017)
TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
Taiwen Li et al.
CANCER RESEARCH (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer
Fumi Sato-Kaneko et al.
JCI INSIGHT (2017)
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nisha Nagarsheth et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Pattern recognition receptors: immune targets to enhance cancer immunotherapy
T. Shekarian et al.
ANNALS OF ONCOLOGY (2017)
Metronomic chemotherapy prevents therapy-induced stromal activation and induction of cancer stem cells
Kelvin K. Tsai et al.
CANCER RESEARCH (2017)
CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer
Chunyan Gu-Trantien et al.
JCI INSIGHT (2017)
Next generation approaches for tumor vaccination
Anand Patel et al.
CHINESE CLINICAL ONCOLOGY (2017)
The Role of Angiogenesis in Cancer Treatment
Mehdi Rajabi et al.
BIOMEDICINES (2017)
Interleukin 21 inhibits cancer-mediated FOXP3 induction in naive human CD4 T cells
Vinodh Kannappan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).
Jerome Galon et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy
Stefani Spranger et al.
CANCER CELL (2017)
Escape from IFN-γ-dependent immunosurveillance in tumorigenesis
Chiou-Feng Lin et al.
JOURNAL OF BIOMEDICAL SCIENCE (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer
Nisha Nagarsheth et al.
CANCER RESEARCH (2016)
An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy
Richard Tavare et al.
CANCER RESEARCH (2016)
Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer
Anna Marie Mulligan et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
Kristina Iribarren et al.
ONCOIMMUNOLOGY (2016)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer
Sylvain Ladoire et al.
AUTOPHAGY (2016)
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Haidong Tang et al.
CANCER CELL (2016)
Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis
Jitka Fucikova et al.
CANCER RESEARCH (2016)
Breaking the DNA damage response to improve cervical cancer treatment
Hylke W. Wieringa et al.
CANCER TREATMENT REVIEWS (2016)
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
Weimin Wang et al.
CELL (2016)
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2016)
Biology and Applications of CRISPR Systems: Harnessing Nature's Toolbox for Genome Engineering
Addison V. Wright et al.
CELL (2016)
Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
Andy J. Minn et al.
CELL (2016)
Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity
Masaki Mandai et al.
CLINICAL CANCER RESEARCH (2016)
Emerging Opportunities and Challenges in Cancer Immunotherapy
Theresa L. Whiteside et al.
CLINICAL CANCER RESEARCH (2016)
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
Priti S. Hegde et al.
CLINICAL CANCER RESEARCH (2016)
Therapeutic utility of the newly discovered properties of interleukin-21
E. Al-Chami et al.
CYTOKINE (2016)
Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
Marie de Charette et al.
EUROPEAN JOURNAL OF CANCER (2016)
CD28 Costimulation: From Mechanism to Therapy
Jonathan H. Esensten et al.
IMMUNITY (2016)
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
Bernhard Mlecnik et al.
IMMUNITY (2016)
Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy
Jae-Hyun Park et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
The host STING pathway at the interface of cancer and immunity
Leticia Corrales et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Interleukin-10: An Immune-Activating Cytokine in Cancer Immunotherapy
Hui Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient
Aude G. Chapuis et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Andras Kotschy et al.
NATURE (2016)
Ionic immune suppression within the tumour microenvironment limits T cell effector function
Robert Eil et al.
NATURE (2016)
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
Olivier De Henau et al.
NATURE (2016)
Neoantigen landscape dynamics during human melanoma-T cell interactions
Els M. E. Verdegaal et al.
NATURE (2016)
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Caroline Wigerup et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Interleukin-7 Modulates Anti-Tumor CD8+ T Cell Responses via Its Action on Host Cells
Katrin Deiser et al.
PLOS ONE (2016)
Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells
Shu Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
The cancer immunogram
Christian U. Blank et al.
SCIENCE (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
A large fraction of HLA class I ligands are proteasome-generated spliced peptides
Juliane Liepe et al.
SCIENCE (2016)
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis
Bernhard Mlecnik et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Vinit Kumar et al.
TRENDS IN IMMUNOLOGY (2016)
Role of interleukin-6 in cancer progression and therapeutic resistance
Neeraj Kumari et al.
TUMOR BIOLOGY (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics
Kutlu Elpek et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
Elliott J. Brea et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
Randy F. Sweis et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade
Ellen Moore et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Xiuyan Wang et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Radiotherapy: Changing the Game in Immunotherapy
Sandra Demaria et al.
TRENDS IN CANCER (2016)
T cell migration, search strategies and mechanisms
Matthew F. Krummel et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities
Luca Antonioli et al.
TRENDS IN CANCER (2016)
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment
Sara Serra et al.
BLOOD ADVANCES (2016)
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting
Belal Chaudhary et al.
VACCINES (2016)
Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer
Sylvain Ladoire et al.
AUTOPHAGY (2015)
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Lorenzo Galluzzi et al.
CANCER CELL (2015)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli et al.
CELL (2015)
Molecular mechanisms of CD8+ T cell trafficking and localization
Jeffrey C. Nolz
CELLULAR AND MOLECULAR LIFE SCIENCES (2015)
Targeting the tumor vasculature to enhance T cell activity
Evripidis Lanitis et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
Designing chimeric antigen receptors to effectively and safely target tumors
Michael C. Jensen et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse
Sarah E. Church et al.
IMMUNITY (2015)
Cancer immunotherapy: harnessing the immune system to battle cancer
Yiping Yang
JOURNAL OF CLINICAL INVESTIGATION (2015)
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
Duane A. Mitchell et al.
NATURE (2015)
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Dongjun Peng et al.
NATURE (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
The prognostic landscape of genes and infiltrating immune cells across human cancers
Andrew J. Gentles et al.
NATURE MEDICINE (2015)
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman et al.
NATURE METHODS (2015)
Oncolytic viruses: a new class of immunotherapy drugs
Howard L. Kaufman et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Targeting the TGFβ pathway for cancer therapy
Cindy Neuzillet et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Could microbial therapy boost cancer immunotherapy?
Alexandra Snyder et al.
SCIENCE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
Erika Vacchelli et al.
SCIENCE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, 0X40, GITR, CD27, CD28, and ICOS
Miguel F. Sanmamed et al.
SEMINARS IN ONCOLOGY (2015)
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
Rikke B. Holmgaard et al.
CELL REPORTS (2015)
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
Leticia Corrales et al.
CELL REPORTS (2015)
Human Tumor Antigens and Cancer Immunotherapy
Nathalie Vigneron
BIOMED RESEARCH INTERNATIONAL (2015)
Targeting ECM disrupts cancer progression
Freja A. Venning et al.
FRONTIERS IN ONCOLOGY (2015)
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
Robert D. Leone et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2015)
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2015)
The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell-Dependent Tumor Immunity
Sara M. Mangsbo et al.
CLINICAL CANCER RESEARCH (2015)
Reactivation of codogenic endogenous retroviral (ERV) envelope genes in human endometrial carcinoma and prestages: Emergence of new molecular targets.
Pamela L. Strissel et al.
Oncotarget (2015)
Type I interferons in anticancer immunity
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor
H. Nishio et al.
BRITISH JOURNAL OF CANCER (2014)
Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8+ T Cells
Jeremy Goc et al.
CANCER RESEARCH (2014)
Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
Maria-Gabriela Anitei et al.
CLINICAL CANCER RESEARCH (2014)
Intratumoral Immunization: A New Paradigm for Cancer Therapy
Aurelien Marabelle et al.
CLINICAL CANCER RESEARCH (2014)
Vector Integration and Tumorigenesis
Christof von Kalle et al.
HUMAN GENE THERAPY (2014)
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Seng-Ryong Woo et al.
IMMUNITY (2014)
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
Liufu Deng et al.
IMMUNITY (2014)
Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways
Patrick L. Raber et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Alena Gros et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours
Jerome Galon et al.
JOURNAL OF PATHOLOGY (2014)
The cGAS-cGAMP-STING Pathway of Cytosolic DNA Sensing and Signaling
Xin Cai et al.
MOLECULAR CELL (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Antonella Sistigu et al.
NATURE MEDICINE (2014)
Functional Network Pipeline Reveals Genetic Determinants Associated with in Situ Lymphocyte Proliferation and Survival of Cancer Patients
Bernhard Mlecnik et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Interferons and Their Stimulated Genes in the Tumor Microenvironment
HyeonJoo Cheon et al.
SEMINARS IN ONCOLOGY (2014)
From Breaking Bad to Worse: Exploiting Homologous DNA Repair Deficiency in Cancer
Michael T. Hemann
CANCER DISCOVERY (2014)
CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful
Hye-Jung Kim et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade
Janis M. Taube
ONCOIMMUNOLOGY (2014)
T-helper 1 immunoreaction influences survival in muscle-invasive bladder cancer: proof of concept
Alexandre Ingels et al.
ECANCERMEDICALSCIENCE (2014)
Achieving cancer cell death with PI3K/mTOR-targeted therapies
Sung Su Yea et al.
INOSITOL PHOSPHOLIPID SIGNALING IN PHYSIOLOGY AND DISEASE (2013)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Yuhui Huang et al.
CANCER RESEARCH (2013)
Tumor Promotion by Intratumoral Plasmacytoid Dendritic Cells Is Reversed by TLR7 Ligand Treatment
Isabelle Le Mercier et al.
CANCER RESEARCH (2013)
Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry
Anna Marie Mulligan et al.
CLINICAL CANCER RESEARCH (2013)
Molecular Pathways: Toll-like Receptors in the Tumor Microenvironment-Poor Prognosis or New Therapeutic Opportunity
Lisa A. Ridnour et al.
CLINICAL CANCER RESEARCH (2013)
Agonistic CD40 Antibodies and Cancer Therapy
Robert H. Vonderheide et al.
CLINICAL CANCER RESEARCH (2013)
Interleukin-15 in Gene Therapy of Cancer
Maria C. Ochoa et al.
CURRENT GENE THERAPY (2013)
From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer
Helen Angel et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/Entpd1 null Mice
Xiaofeng Sun et al.
HEPATOLOGY (2013)
The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
Jerome Galon et al.
IMMUNITY (2013)
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Gabriela Bindea et al.
IMMUNITY (2013)
Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy
Fernando Ulloa-Montoya et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
Inhibition of Tumor Angiogenesis by Interferon-gamma by Suppression of Tumor-Associated Macrophage Differentiation
Tao Sun et al.
ONCOLOGY RESEARCH (2013)
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Sophie Viaud et al.
SCIENCE (2013)
Immunity, inflammation and cancer: a leading role for adenosine
Luca Antonioli et al.
NATURE REVIEWS CANCER (2013)
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study
Youn H. Kim et al.
BLOOD (2012)
An immune-active tumor microenvironment favors clinical response to ipilimumab
Rui-Ru Ji et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma
Valerie Chew et al.
GUT (2012)
The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells
Alexander Shimabukuro-Vornhagen et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2012)
CD8 T Cell Priming in the Presence of IFN-α Renders CTLs with Improved Responsiveness to Homeostatic Cytokines and Recall Antigens: Important Traits for Adoptive T Cell Therapy
Sandra Hervas-Stubbs et al.
JOURNAL OF IMMUNOLOGY (2012)
Immune Suppression and Resistance Mediated by Constitutive Activation of Wnt/β-Catenin Signaling in Human Melanoma Cells
Tomonori Yaguchi et al.
JOURNAL OF IMMUNOLOGY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Leukocyte composition of human breast cancer
Brian Ruffell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Vascular Normalization as a Therapeutic Strategy for Malignant and Nonmalignant Disease
Shom Goel et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Trial watch Dendritic cell-based interventions for cancer therapy
Lorenzo Galluzzi et al.
ONCOIMMUNOLOGY (2012)
Targeting PD-1/PD-L1 interactions for cancer immunotherapy
Laurence Zitvogel et al.
ONCOIMMUNOLOGY (2012)
Immunogenic cell death and DAMPs in cancer therapy
Dmitri V. Krysko et al.
NATURE REVIEWS CANCER (2012)
The molecular basis of the memory T cell response: differential gene expression and its epigenetic regulation
Nan-ping Weng et al.
NATURE REVIEWS IMMUNOLOGY (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis
John Stagg et al.
CANCER RESEARCH (2011)
The Two Faces of Interferon-γ in Cancer
M. Raza Zaidi et al.
CLINICAL CANCER RESEARCH (2011)
The prognostic value of histological tumor necrosis in solid organ malignant disease: a systematic review
Colin H. Richards et al.
FUTURE ONCOLOGY (2011)
Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction
Bernhard Mlecnik et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Enhanced Cancer Immunotherapy Using STAT3-Depleted Dendritic Cells with High Th1-Inducing Ability and Resistance to Cancer Cell-Derived Inhibitory Factors
Tomoko Iwata-Kajihara et al.
JOURNAL OF IMMUNOLOGY (2011)
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Peter Carmeliet et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity
Abujiang Pataer et al.
CANCER BIOLOGY & THERAPY (2010)
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
Julie Vincent et al.
CANCER RESEARCH (2010)
Decoding Cell Death Signals in Inflammation and Immunity
Laurence Zitvogel et al.
CELL (2010)
TGF beta, a Potent Regulator of Tumor Microenvironment and Host Immune Response, Implication for Therapy
L. Yang
CURRENT MOLECULAR MEDICINE (2010)
Biology of interleukin-10
Robert Sabat et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2010)
Biomolecular Network Reconstruction Identifies T-Cell Homing Factors Associated With Survival in Colorectal Cancer
Bernhard Mlecnik et al.
GASTROENTEROLOGY (2010)
Microsatellite Instability in Colorectal Cancer
C. Richard Boland et al.
GASTROENTEROLOGY (2010)
Regulation of Human Endogenous Retrovirus-K Expression in Melanomas by CpG Methylation
Sven Stengel et al.
GENES CHROMOSOMES & CANCER (2010)
IL-21 and T follicular helper cells
Rosanne Spolski et al.
INTERNATIONAL IMMUNOLOGY (2010)
Found in translation: the human equivalent of mouse CD8+ dendritic cells
Jose A. Villadangos et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Extracellular adenosine triphosphate and adenosine in cancer
J. Stagg et al.
ONCOGENE (2010)
Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia
M. Wemeau et al.
CELL DEATH & DISEASE (2010)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M. L. Ebos et al.
CANCER CELL (2009)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Coordination of Intratumoral Immune Reaction and Human Colorectal Cancer Recurrence
Matthieu Camus et al.
CANCER RESEARCH (2009)
Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
Helena Harlin et al.
CANCER RESEARCH (2009)
Genetic and epigenetic networks controlling T helper 1 cell differentiation
Katarzyna Placek et al.
IMMUNOLOGY (2009)
In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer
Franck Pages et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself
Jiali Li et al.
JOURNAL OF IMMUNOLOGY (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Interleukin-7 receptor expression: intelligent design
Renata Mazzucchelli et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
The adaptive immunologic microenvironment in colorectal cancer: A novel perspective
Jerome Galon et al.
CANCER RESEARCH (2007)
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway
Brian T. Fife et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
Hidetoshi Sumimoto et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
VEGF inhibitors in cancer therapy
AR Cardones et al.
CURRENT PHARMACEUTICAL DESIGN (2006)
Effector memory T cells, early metastasis, and survival in colorectal cancer
F Pagès et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator
JR Sedy et al.
NATURE IMMUNOLOGY (2005)
Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference
H Sumimoto et al.
ONCOGENE (2004)
Mechanisms and functional significance of tumour-induced dendritic-cell defects
D Gabrilovich
NATURE REVIEWS IMMUNOLOGY (2004)
T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody
AL Tutt et al.
JOURNAL OF IMMUNOLOGY (2002)
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
V Shankaran et al.
NATURE (2001)
分享论文
